Abstract:ABSTRACT Genetically-engineered immune cell therapies have been in development for decades 1–3 and recently have proven effective to treat some types of cancer 4 . CRISPR-based genome editing methods, enabling more flexible and targeted sequence integrations than viral transduction, have the potential to extend the clinical utility of cell therapies 5,6 . Realization of this potential depends on improved knowledge of how coding and non-coding sites throughout the genome can be modified efficiently and on improved methods to discover novel synthetic DNA sequences that can be introduced at targeted sites to enhance critical immune cell functions. Here, we developed improved guidelines for non-viral genome targeting in human T cells and a pooled discovery platform to identify synthetic genome modifications that enhance therapeutically-relevant cell functions. We demonstrated the breadth of targetable genomic loci by performing large knock-ins at 91 different genomic sites in primary human T cells, and established the power of flexible genome targeting by generating cells with Genetically Engineered Endogenous Proteins (GEEPs) that seamlessly integrate synthetic and endogenous genetic elements to alter signaling input, output, or regulatory control of genes encoding key immune receptors. Motivated by success in introducing synthetic circuits into endogenous sites, we then developed a platform to facilitate discovery of novel multi-gene sequences that reprogram both T cell specificity and function. We knocked in barcoded pools of large DNA sequences encoding polycistronic gene programs. High-throughput pooled screening of targeted knock-ins to the endogenous T cell receptor (TCR) locus revealed a transcriptional regulator and novel protein chimeras that combined with a new TCR specificity to enhance T cell responses in the presence of suppressive conditions in vitro and in vivo . Overall, these pre-clinical studies provide flexible tools to discover complex synthetic gene programs that can be written into targeted genome sites to generate more effective therapeutic cells.

Quantitative Control of Gene-Engineered T-Cell Activity through the Covalent Attachment of Targeting Ligands to a Universal Immune Receptor

Versatile strategy for controlling the specificity and activity of engineered T cells

Sensitive and adaptable pharmacological control of CAR T cells through extracellular receptor dimerization

Sensitive manipulation of CAR T cell activity using a chimeric endocytosing receptor

Engineered reversible inhibition of SpyCatcher reactivity enables rapid generation of bispecific antibodies

Rapid discovery of synthetic DNA sequences to rewrite endogenous T cell circuits

Programmable synthetic receptors: the next-generation of cell and gene therapies.

Refining chimeric antigen receptors via barcoded protein domain combination pooled screening

Aptamer-Based Nongenetic Reprogramming of CARs Enables Flexible Modulation of T Cell-Mediated Tumor Immunotherapy

Universal redirection of CAR T cells against solid tumours via membrane-inserted ligands for the CAR

Antibody-targeted T cells and natural killer cells for cancer immunotherapy

A Customizable Platform to Integrate CAR and Conditional Expression of Immunotherapeutics in T Cells

Nano-Biohybrid DNA Engager That Reprograms the T-Cell Receptor

A chimeric antigen receptor-based cellular safeguard mechanism for selective in vivo depletion of engineered T cells

A Robotic Microscope System To Examine T Cell Receptor Acuity Against Tumor Neoantigens: A New Tool For Cancer Immunotherapy Research

Direct control of CAR T cells through small molecule-regulated antibodies

A high throughput microelectroporation device to introduce a chimeric antigen receptor to redirect the specificity of human T cells

Universal Chimeric Antigen Receptors for Multiplexed and Logical Control of T Cell Responses

A Chimeric Conjugate of Antibody and Programmable DNA Nanoassembly Smartly Activates T Cells for Precise Cancer Cell Targeting

Arming Immune Cell Therapeutics with Polymeric Prodrugs

Engineering AvidCARs for combinatorial antigen recognition and reversible control of CAR function